Belzutifan special drug use results survey in radically unresectable or metastatic renal cell carcinoma: a postauthorization safety study (PASS) (MK-6482-045)

20/02/2026
22/05/2026
EU PAS number:
EUPAS1000000880
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

6482-045-01-v0-with-ha-approval-date_final-redaction.pdf

English (464.79 KB - PDF) View document
Study results
Study report
Other information